TomTom and PSA Group Drive EU Ministers in Autonomous Vehicles
TomTom (TOM2) today announced it collaborated with PSA Group participating in an EU gathering of top politicians in the Dutch capital. TomTom provided HD Maps to enable PSA Group to participate in the self-driving car demonstration in Amsterdam.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160414006360/en/
HD Map (Photo: Business Wire)
EU Commissioner for Transport Violeta Bulc and 28 EU Transport Ministers gathered here, under the Dutch EU presidency, to work toward eliminating regulatory and technical barriers around autonomous driving. The vehicles were used in a demonstration during the event, driving the Ministers autonomously in real traffic conditions.
"TomTom is delighted that the Dutch presidency is taking the initiative to accelerate innovation and development around autonomous driving in the EU,” said Antoine Saucier, Managing Director for TomTom Automotive. “We are excited to work with PSA Group to support this event and to play a role in enabling the automotive industry to move closer to making autonomous driving a reality”.
TomTom HD Map and RoadDNA are two revolutionary, highly accurate digital map products helping automated vehicles precisely locate themselves on the road and plan manoeuvres, even when traveling at high speeds. Launched commercially in 2015, these new technologies are being rolled out in strategic geographies and are the subject of key partnerships with other automotive suppliers.
– Ends –
At TomTom (TOM2) our mission is to make technology so easy to use, that everyone can benefit from it.
We created easy to use navigation devices, helping millions of people to get where they want to be. Today, we continue to simplify the complex, making technology more accessible for everyone.
We have four customer facing business units: Consumer, Telematics, Automotive and Licensing.
We make easy to use navigation devices, sport watches and action cameras for consumers. We enable businesses with vehicles to more easily manage and improve fleet efficiency whilst increasing overall business performance with our Telematics solutions. We also offer a world leading real-time map platform that is powering innovative location based services and helping to make automated driving a reality for the automotive industry.
Founded in 1991 and headquartered in Amsterdam, we have over 4,600 employees and sell our products worldwide.
About TomTom Automotive
TomTom Automotive is the trusted partner for innovative and future-proof navigation technology for the global automotive industry. As a global leader in connected navigation software, traffic information, and digital real-time maps, we offer Automotive OEMs the modular components to create competitive infotainment systems, as well as the technology to enable the future self-driving cars to see beyond their sensors.
Director Group Communications
+31 (0)20 75 74 135
Head of Treasury and Investor Relations
+31 20 75 75 194
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
BearingPoint: How Firms Transform into Digital Superpowers22.2.2018 08:30 | Pressemelding
Digital disruption has left Europe’s leading companies struggling to sustain growth and competitive advantage. Groundbreaking new research reveals how European companies can learn from US digital superpowers to speed up adoption of business model innovation, drive new revenues and get greater value from their core business. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222005241/en/ Diversifying business model Portfolio (Graphic: Business Wire) Today, firms that adopt a portfolio of business models which are asset light and include network effects are perceived by investors and the market as most likely to generate future growth. They therefore have a much higher market value in comparison to companies with traditional business models. Companies who diversified their business models improved their valuation in 2016 by 65% in comparison to those who maintained a mono-business model. Furthermore, between 2011-2016 they mana
Eli Global to Acquire Lead Generation Marketplace Finanzen22.2.2018 08:00 | Pressemelding
Eli Global LLC (“Eli”) today announced that an affiliate has entered into a definitive agreement to acquire finanzen.de AG and its subsidiaries (collectively, “Finanzen” or the “company”) from Blackfin Capital Partners (“Blackfin”) and Finanzen’s founders. Based in Berlin, Germany, Finanzen is the leading European online marketplace for retail customer leads in the finance and insurance sectors. The company connects lead generators such as online price comparison sites with lead buyers such as independent financial advisors and insurance agents. The company also acts as an online broker for certain insurance products. “Finanzen has done an impressive job creating a scalable technology platform poised to benefit from industry trends,” said George Luecke, global manager of Eli’s newly established insurance services portfolio and co-CEO of Global Bankers Insurance Group, which represents Eli’s life and annuity carrier division (“GBIG”). “We look forward to a long-term future with the comp
Ferring Pharmaceuticals and MSD Announce Completion of Largest Clinical Trial Ever Conducted in Postpartum Haemorrhage22.2.2018 06:00 | Pressemelding
Ferring Pharmaceuticals and MSD, known as Merck & Co., Inc., Kenilworth, N.J., U.S.A., through its MSD for Mothers initiative, today announced the completion of CHAMPION (Carbetocin Haemorrhage Prevention), a global clinical trial conducted by the Human Reproduction Program (HRP) at the World Health Organization (WHO). CHAMPION is investigating whether Ferring’s proprietary and heat-stable carbetocin could offer a new solution to prevent excessive bleeding after childbirth (postpartum haemorrhage or PPH).2,3 Involving nearly 30,000 women in 10 countries, it is the largest clinical trial ever conducted in PPH.2,3 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221006496/en/ Each year, 14 million mothers are affected by PPH.4 As the leading direct cause of maternal mortality, 480,000 mothers died from PPH between 2003-09.1 Even when women survive, PPH can result in the need for serious medical interventions, including surgica
The Nippon Foundation: Project to Map Ocean Floor by 2030 Now Operational22.2.2018 05:00 | Pressemelding
The Nippon Foundation Chairman Yohei Sasakawa announced at a press conference today that The Nippon Foundation – GEBCO Seabed 2030 Project is now operational. The Project will realize Mr. Sasakawa’s vision of mapping the entire ocean floor by 2030. The Nippon Foundation has pledged US$2 million annually, and is calling for additional support from the global ocean community. Mr. Sasakawa noted, “The Nippon Foundation alone cannot achieve the objectives of this ambitious project. We will need the support of diverse stakeholders, including maritime corporations and technical experts. It is crucial that the ocean community comes together to achieve this goal”. He was joined by leading ocean-mapping experts, who emphasized that understanding the bathymetry of the global ocean is imperative for improving maritime navigation, and also for enhancing our ability to predict climate change and monitor marine biodiversity and resources. A comprehensive map of the seafloor will assist global effort
Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis21.2.2018 21:01 | Pressemelding
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it is initiating the first Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation. The study will enroll 360 patients, and the primary endpoint of the study is the mean absolute change from baseline in percent predicted forced expiratory volume in one second (ppFEV1) at week four of treatment. The study is designed to support the submission of a New Drug Application (NDA) in the U.S. using data from the 4-week primary efficacy endpoint together with safety data through 12 weeks of treatment. “Our goal is to bring the best triple combination to patients as rapidly as possible, and this first Phase 3 study of VX-659 in combination with tezacaftor and ivacaftor is a significant step toward that goal,” said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical
Universal Laser Systems® Expands Portfolio of Laser Material Processing Systems with the ULTRA Platform Series21.2.2018 18:00 | Pressemelding
ULTRA platform-based laser systems are designed and ideally suited for precision laser cutting, laser ablation, and laser surface modification in manufacturing, research and development, academic research and prototyping environments. Major features of the series include rapid, high-accuracy laser beam positioning, and the flexibility to be configured with 9.3 and 10.6 µm CO2 lasers and 1.06 µm fiber lasers. All lasers are air-cooled in a range of power from 10 to 150 watts for CO2 and 40 to 50 watts for fiber lasers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005364/en/ The ULTRA 9MW offers MultiWave processing of thin materials. (Photo: Business Wire) The variety of wavelengths and power ranges make the ULTRA platforms highly effective in the areas of organic material modification, including plastic films, industrial fabrics, engineering plastics, laminating adhesives, composite materials, and many others utilized